The Protective Effect of Cynara Cardunculus Extract in Diet-Induced NAFLD: Involvement of OCTN1 and OCTN2 Transporter Subfamily

Nutrients. 2020 May 15;12(5):1435. doi: 10.3390/nu12051435.

Abstract

Hyperlipidemia and insulin-resistance are often associated with Non-Alcoholic Fatty Liver Disease (NAFLD) thereby representing a true issue worldwide due to increased risk of developing cardiovascular and systemic disorders. Although clear evidence suggests that circulating fatty acids contribute to pathophysiological mechanisms underlying NAFLD and hyperlipidemia, further studies are required to better identify potential beneficial approaches for counteracting such a disease. Recently, several artichoke extracts have been used for both reducing hyperlipidemia, insulin-resistance and NAFLD, though the mechanism is unclear. Here we used a wild type of Cynara Cardunculus extract (CyC), rich in sesquiterpens and antioxidant active ingredients, in rats fed a High Fat Diet (HFD) compared to a Normal Fat Diet (NFD). In particular, in rats fed HFD for four consecutive weeks, we found a significant increase of serum cholesterol, triglyceride and serum glucose. This effect was accompanied by increased body weight and by histopathological features of liver steatosis. The alterations of metabolic parameters found in HFDs were antagonised dose-dependently by daily oral supplementation of rats with CyC 10 and 20 mg/kg over four weeks, an effect associated to significant improvement of liver steatosis. The effect of CyC (20 mg/kg) was also associated to enhanced expression of both OCTN1 and OCTN2 carnitine-linked transporters. Thus, present data suggest a contribution of carnitine system in the protective effect of CyC in diet-induced hyperlipidemia, insulin-resistance and NAFLD.

Keywords: Non-Alcoholic Fatty Liver Disease (NAFLD); OCTN1; OCTN2; hyperlipidemia; insulin-resistance.

MeSH terms

  • Animals
  • Blood Glucose / drug effects
  • Cholesterol / blood
  • Cynara*
  • Diet, High-Fat / adverse effects
  • Dietary Supplements
  • Hyperlipidemias / blood
  • Hyperlipidemias / drug therapy
  • Hyperlipidemias / etiology
  • Insulin Resistance
  • Male
  • Non-alcoholic Fatty Liver Disease / blood
  • Non-alcoholic Fatty Liver Disease / drug therapy*
  • Non-alcoholic Fatty Liver Disease / etiology
  • Organic Cation Transport Proteins / drug effects*
  • Plant Extracts / pharmacology*
  • Protective Agents / pharmacology*
  • Rats
  • Rats, Sprague-Dawley
  • Solute Carrier Family 22 Member 5 / drug effects*
  • Symporters / drug effects*
  • Triglycerides / blood

Substances

  • Blood Glucose
  • Organic Cation Transport Proteins
  • Plant Extracts
  • Protective Agents
  • Slc22a4 protein, rat
  • Slc22a5 protein, rat
  • Solute Carrier Family 22 Member 5
  • Symporters
  • Triglycerides
  • Cholesterol